Lynch & Associates IN lowered its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 96,114 shares of the company’s stock after selling 568 shares during the quarter. Johnson & Johnson comprises approximately 4.4% of Lynch & Associates IN’s portfolio, making the stock its 2nd largest holding. Lynch & Associates IN’s holdings in Johnson & Johnson were worth $16,978,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its position in Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after acquiring an additional 3,912,430 shares in the last quarter. FMR LLC raised its stake in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares during the period. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after purchasing an additional 2,815,655 shares in the last quarter. GQG Partners LLC boosted its stake in shares of Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after purchasing an additional 2,093,392 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.35% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
A number of research firms have weighed in on JNJ. Guggenheim assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday. They set a “strong-buy” rating for the company. Citigroup upped their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 25th. Finally, Atlantic Securities increased their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $174.73.
Johnson & Johnson Trading Down 0.2 %
Johnson & Johnson stock opened at $154.03 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. Johnson & Johnson has a 1 year low of $150.71 and a 1 year high of $186.69. The firm’s 50-day moving average is $162.52 and its 200-day moving average is $167.95. The company has a market cap of $401.14 billion, a P/E ratio of 22.85, a PEG ratio of 2.65 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. During the same quarter last year, the company posted $2.13 earnings per share. On average, equities analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 67.06%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.